Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept AFFINITY Study

The study aimed to evaluate the efficacy of a combination therapy of guselkumab and golimumab compared to guselkumab monotherapy in patients with active psoriatic arthritis (PsA) who had an inadequate response to tumor necrosis factor inhibitors. While the primary endpoint of achieving minimal disease activity at week 24 was not met, secondary analyses indicated that the combination therapy provided significant benefits, particularly for patients with elevated C-reactive protein levels, without introducing new safety concerns. These findings suggest that further investigation into the combination therapy's potential is warranted.